EVAS与EVAR中期结局的系统综述
该系统综述纳入12项研究共10255例患者(EVAS 784例,EVAR 9441例),比较EVAS与EVAR的中期结局。EVAS全因死亡率和内漏率有更低趋势,但移植物迁移、动脉瘤增长和再干预率更高,异质性>50%限制稳健分析。
要点
- EVAS全因死亡率6%低于EVAR的13%,但异质性>50%限制稳健比较
- EVAS迁移>10mm为8%而EVAR为0%,动脉瘤增长>5mm为11% vs 3%
- EVAS再干预率13%高于EVAR的7%,内漏类型分布有差异趋势
核心结论
- EVAS相比EVAR有更低的全因死亡率和总体内漏率趋势,但迁移、动脉瘤增长和再干预率更高。
- 尽管EVAS总体内漏率更低,但趋势显示EVAS后II型内漏更少而I型内漏更多。
- 显著异质性(>50%)限制稳健统计分析,可能源于EVAS患者中显著的说明书使用违规。
研究设计与样本
- 按照PRISMA指南进行的系统综述和分析。
- 检索PubMed、Embase和Cochrane Library,纳入12项研究(EVAS 4项,EVAR 8项),共10255例患者(EVAS 784例,EVAR 9441例)。
- EVAS研究最长随访3.4年,EVAR研究最长随访5.0年。
主要发现
- 随访期间全因死亡率EVAS为6%,EVAR为13%。
- 任何类型内漏EVAS为10%,EVAR为17%。
- 迁移>10mm EVAS为8%,EVAR为0%;动脉瘤增长>5mm EVAS为11%,EVAR为3%。
- 总再干预率EVAS为13%,EVAR为7%。
- 所有分析结局参数的异质性均>50%。
临床怎么用
- 临床决策时应权衡EVAS较低死亡率和内漏率趋势与其较高的迁移、动脉瘤增长和再干预风险。
- 需注意EVAS患者中说明书使用违规可能影响结局比较的可靠性。
局限性
- 显著异质性(>50%)限制稳健统计分析。
- 异质性可能源于EVAS治疗患者中显著的说明书使用违规。
- 需要更多高质量和长期随访研究来确认本研究的趋势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The Nellix endovascular aneurysm sealing (EVAS) system has been a topic of discussion. Early results were promising but did not deliver on the long-term and the device has been recalled from the market. This study compares literature for EVAS and conventional endovascular aneurysm repair (EVAR). METHODS: A systematic review and analysis was conducted according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. PubMed, Embase, and Cochrane Library were searched and identified the eligible studies. Proportion rates for the outcomes of interest were extracted. Subgroup analyses were performed for EVAS and EVAR. RESULTS: A total of 12 studies were included (EVAS n = 4, EVAR n = 8) including 10,255 patients (EVAS n = 784, EVAR n = 9441). The longest duration of follow-up was 3.4 years for EVAS and 5.0 years for EVAR studies. Throughout follow-up the overall all-cause mortality rates were 6% for EVAS and 13% for EVAR, and endoleak of any type was described in 10% of EVAS and 17% of EVAR patients. The migration rate >10 mm was 8% for EVAS and 0% for EVAR and aneurysm growth >5 mm was found in 11% of EVAS and 3% of EVAR cases. Total reintervention rate was 13% for EVAS and 7% for EVAR patients. For all analyzed outcome parameters heterogeneity was >50%. CONCLUSION: There is a tendency toward lower mortality and overall endoleak rates for EVAS compared to EVAR but with a higher rate of migration, aneurysm growth, and reintervention. Despite lower overall endoleak rates there was a tendency toward less type II and more type I endoleaks after EVAS compared to EVAR. Substantial heterogeneity however limits robust statistical analyses, and is probably caused by significant instructions for use breach in EVAS-treated patients. We call for more high-quality and long-term follow-up studies on both EVAS and EVAR in order to confirm the trends found in this study.
引用
- Zoethout AC, Hochstenbach I, van der Laan MJ, et al. Systematic Review on the Mid-Term Outcomes of Elective Endovascular Aneurysm Sealing in Comparison to Endovascular Aneurysm Repair. J Endovasc Ther. 2021. PMID: 34569337. doi:10.1177/15266028211047941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。